ストックスクリーナーアプリを入手
17.94
0.17%
-0.03
前日終値:
$17.97
開ける：
$17.93
24時間の取引高:
335.98K
Relative Volume:
0.51
時価総額：
$2.32B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-3.86%
1か月 パフォーマンス:
-5.63%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$17.47
$18.39
1週間の範囲:
$17.47
$19.51
52週間の値動き範囲:
$16.39
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Compare KLRA vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
17.94 | 2.41B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-05-12 | 開始されました | Evercore ISI | Outperform |
| 2026-05-12 | 開始されました | JP Morgan | Overweight |
| 2026-05-12 | 開始されました | Jefferies | Buy |
| 2026-05-12 | 開始されました | Leerink Partners | Outperform |
| 2026-05-12 | 開始されました | TD Cowen | Buy |
| 2026-05-12 | 開始されました | William Blair | Outperform |
すべてを表示
Kailera Therapeutics Inc (KLRA) 最新ニュース
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing - Stock Titan
RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G - Stock Titan
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30 - Moomoo
KLRA SWOT Analysis: Financial Challenges and Growth Potential Revealed in 10-Q Filing - GuruFocus
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings - Quiver Quantitative
Kailera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kailera Q2 loss widens 285% to $111.3M on R&D surge; cash runway extends to mid-2028 - scanx.trade
Kailera Therapeutics Submits Q2 2026 10-Q Highlighting Financial Status and Operational Risks - Kalkine Media
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Nigeria
Kailera Therapeutics, Inc. 2Q 2026: Revenue N/A, Net loss $(111.3M), EPS $(1.09) — 10-Q Summary - TradingView
KLRA: Q2 net loss rose to $111.3M on higher R&D; $1.17B cash post-IPO funds operations into mid-2028 - tradingview.com
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Kailera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kailera Therapeutics, Inc. Announces Appointment of Nur Nicholson as Chief Technology Officer, Effective August 31, 2026 - marketscreener.com
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer - The Manila Times
Kailera Therapeutics Inc expected to post a loss of 75 cents a shareEarnings Preview - TradingView
Jiangsu Hengrui discloses 8.9% Kailera Therapeutics (KLRA) stake in ownership filing - Stock Titan
Bain Capital Xiv General Partner, Llc Net Worth (2026) - GuruFocus
Kailera Therapeutics, Inc. Revenue Breakdown – NASDAQ:KLRA - TradingView
Kailera Therapeutics (KLRA) Stock Price, News & Analysis $KLRA - MarketBeat
Patent fight erupts around next generation of multibillion-dollar GLP-1 weight-loss drugs - The Business Journals
Yuting Liu Net Worth (2026) - GuruFocus
Jamie Beth Coleman Net Worth (2026) - GuruFocus
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Net Worth (2026) - GuruFocus
Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
Scott M. Wasserman Net Worth (2026) - GuruFocus
Stuart Partners, Llc Net Worth (2026) - GuruFocus
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Up 96.0% in June - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week LowWhat's Next? - MarketBeat
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential - Yahoo Finance
Kailera's obesity drug meets main goal of late-stage trials in China - MSN
Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win - Seeking Alpha
5 Best IPO Stocks with Huge Upside Potential - Insider Monkey
Kailera Therapeutics (KLRA) officer receives 175,000 stock options at $23.30 strike - Stock Titan
Kailera Therapeutics (KLRA) officer Kathleen Tregoning files initial Form 3 - Stock Titan
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Kailera weight loss pill trial results: Nausea sinks stock - qz.com
Europe will accelerate its review of RevMed’s drug - STAT
Kailera reports positive Phase III data for oral GLP-1 obesity candidate - The Pharma Letter
Kailera shares tumble on high nausea rates despite weight-loss drug's success | Business Information & News | FE - Westlaw Today
Kailera Therapeutics (KLRA) Company presentation Summary - Quartr
Kailera Therapeutics (KLRA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Kailera Therapeutics (KLRA) Registration filing Summary - Quartr
Kailera falls after late-stage trial data for oral GLP-1 candidate - MSN
Kailera/Hengrui’s Oral GLP-1 Looks Effective, But GI Toxicity Raises Concern - insights.citeline.com
Kailera shares tumble on high nausea rates despite weight-loss drug's success - MSN
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall - Moomoo
Kailera shares tumble on high nausea rates despite weight-loss drug’s success - Y100 WNCY
Kailera Therapeutics Inc (KLRA) 財務データ
Kailera Therapeutics Inc (KLRA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):